{"doi":"10.2745/dds.32.126","title":"Brentuximab vedotin. an antibody-drug conjugate targeting CD30","abstract":null,"journal":"Drug Delivery System","year":2017,"id":645390,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":213603,"name":"Tomoko Yanai","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Brentuximab vedotin. an antibody-drug conjugate targeting CD30","abstract":"Brentuximab vedotin（BV）はCD30を標的とする抗体薬物複合体であり、効能・効果はCD30陽性再発・難治性ホジキンリンパ腫と未分化大細胞リンパ腫である。BVがCD30発現細胞に取り込まれると、MMAEが微小管に結合しアポトーシスを誘導する。重大な副作用として、末梢神経障害、感染症、骨髄抑制、infusion reactionなどがあげられる。他の抗悪性腫瘍剤との併用における有効性・安全性は確立していない。未治療HLと未治療CD30陽性成熟型T細胞リンパ腫を対象としたBV併用化学療法に関する国際第Ⅲ相臨床試験の結果が待たれる。","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19910364","pmcid":null,"openalex_id":"https://openalex.org/W2659988585","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.07834587,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":null,"oa_locations":[{"url":"https://www.jstage.jst.go.jp/article/dds/32/2/32_126/_pdf","host_type":"journal"},{"url":"https://www.jstage.jst.go.jp/article/dds/32/2/32_126/_pdf","host_type":"publisher"},{"url":"https://doi.org/10.2745/dds.32.126","host_type":"journal"}],"fields_of_study":["HER2/EGFR in Cancer Research","Lymphoma Diagnosis and Treatment","Monoclonal and Polyclonal Antibodies Research"],"mesh_terms":[],"keywords":["Brentuximab vedotin","Antibody-drug conjugate","Conjugate","Antibody","Drug","CD30","Medicine","Pharmacology","Chemistry","Monoclonal antibody","Cancer research","Immunology","Mathematics","Tumor cells"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-09T05:16:26.122843Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}